We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.

Skip to main content

The Jackson Laboratory

Home

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

Home
Short Videos
Immunomodulatory Profile

Immunomodulatory Profile

Published Date August 28, 2023

Bispecifics and CAR-T sequences

No Previous Videos
Next Video

CD34+ Humanized Mice

Human cord blood-derived hematopoietic CD34+ stem cells. Validated: greater than 25% human CD45+ cells in peripheral blood. Humanized NSG variants (hu-CD34+). Infectious disease, gene therapy, cancer,

Most Recent Videos

over 1 year ago
CD34+ Humanized Mice

Human cord blood-derived hematopoietic CD34+ stem cells. Validated: greater than 25% human CD45+ cells in peripheral blood. Humanized NSG variants (hu-CD34+). Infectious disease, gene therapy, cancer,

Watch Video
over 1 year ago
CAR T studies with significantly delayed onset of GvHD

Assessing efficacy and toxicity in CAR-T studies in an accessible translational model. The Jackson Laboratory's in vivo PBMC-humanized mouse platform provides a wider window to look at cytokine releas

Watch Video
almost 2 years ago
FcRn model platform

The FcRn platform from The Jackson Laboratory mimics specific aspects of the human IgG physiology providing the ideal model platform to assess the pharmacokinetics (PK) of therapeutic antibody candida

Watch Video
over 2 years ago
FcRn and the Long Half-Life of IgG Antibodies

A really important component of IgG antibodies is their ability to have a really long half-life in circulation, as opposed to other Ig subclasses. Lower pH causes the IgG antibodies, not the IgM or I

Watch Video
over 2 years ago
The New Era For In Vivo Immunotherapy Testing Is Here

Immunomodulatory therapies are the latest weapon to be added to the cancer-fighting arsenal. These therapies work by generating or augmenting the immune response to a tumor. Discovering and validating

Watch Video
about 3 years ago
CRS Model Platform

With The Jackson Laboratory’s novel humanized mouse models for CRS, you can test for both, immunotoxicity, and drug efficacy at the same time. You can test candidate therapies, with or without the pre

Watch Video
almost 4 years ago
What is Cytokine Release Syndrome?

What is Cytokine Release Syndrome? CRS occurs when the innate and adaptive immune systems are overactivated, releasing too many cytokines, which are substances that can affect other cells.

Watch Video

Return to Home